Beaune P[au] - Search Results

Year	Number of Results
1976	1
1977	2
1978	2
1979	2
1980	3
1981	5
1982	2
1983	6
1984	3
1985	8
1986	8
1987	3
1988	2
1989	5
1990	8
1991	8
1992	9
1993	23
1994	13
1995	15
1996	19
1997	11
1998	7
1999	10
2000	13
2001	11
2002	7
2003	11
2004	8
2005	13
2006	10
2007	13
2008	12
2009	12
2010	13
2011	6
2012	7
2013	3
2014	12
2015	8
2016	7
2017	3
2018	1
2019	1
2020	1
2021	2

1

Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders.

Villoutreix BO, Beaune PH, Tamouza R, Krishnamoorthy R, Leboyer M. Villoutreix BO, et al. Among authors: beaune ph. Drug Discov Today. 2020 Aug;25(8):1287-1290. doi: 10.1016/j.drudis.2020.06.022. Epub 2020 Jun 25. Drug Discov Today. 2020. PMID: 32593662 Free PMC article. No abstract available.

2

Drug-induced immunotoxicity.

Dansette PM, Bonierbale E, Minoletti C, Beaune PH, Pessayre D, Mansuy D. Dansette PM, et al. Among authors: beaune ph. Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):443-51. doi: 10.1007/BF03189993. Eur J Drug Metab Pharmacokinet. 1998. PMID: 10323325 Review.

3

[Diet, genetics and cancer].

Beaune P. Beaune P. Gastroenterol Clin Biol. 2001 Apr;25(4 Suppl):B20-5. Gastroenterol Clin Biol. 2001. PMID: 11449141 Free article. Review. French. No abstract available.

4

Polymorphism of human cytochrome P-450.

Guengerich FP, Umbenhauer DR, Churchill PF, Beaune PH, Böcker R, Knodell RG, Martin MV, Lloyd RS. Guengerich FP, et al. Among authors: beaune ph. Xenobiotica. 1987 Mar;17(3):311-6. doi: 10.3109/00498258709043941. Xenobiotica. 1987. PMID: 3577206

5

[mTOR inhibitors: pleiotropic antiproliferative drugs].

Pallet N, Beaune P, Thervet E, Legendre C, Anglicheau D. Pallet N, et al. Among authors: beaune p. Med Sci (Paris). 2006 Nov;22(11):947-52. doi: 10.1051/medsci/20062211947. Med Sci (Paris). 2006. PMID: 17101096 Free article. Review. French.

6

Cytochrome P450 3A polymorphisms and immunosuppressive drugs.

Thervet E, Legendre C, Beaune P, Anglicheau D. Thervet E, et al. Among authors: beaune p. Pharmacogenomics. 2005 Jan;6(1):37-47. doi: 10.1517/14622416.6.1.37. Pharmacogenomics. 2005. PMID: 15723604 Review.

7

Role of pharmacogenetics of immunosuppressive drugs in organ transplantation.

Thervet E, Anglicheau D, Legendre C, Beaune P. Thervet E, et al. Among authors: beaune p. Ther Drug Monit. 2008 Apr;30(2):143-50. doi: 10.1097/FTD.0b013e31816babef. Ther Drug Monit. 2008. PMID: 18367973 Review.

8

Recombinant yeast in drug metabolism.

Renaud JP, Peyronneau MA, Urban P, Truan G, Cullin C, Pompon D, Beaune P, Mansuy D. Renaud JP, et al. Among authors: beaune p. Toxicology. 1993 Oct 5;82(1-3):39-52. doi: 10.1016/0300-483x(93)90058-z. Toxicology. 1993. PMID: 8236280 Review.

9

Mesenchymal stem cells as cellular vehicles for prodrug gene therapy against tumors.

Amara I, Touati W, Beaune P, de Waziers I. Amara I, et al. Among authors: beaune p. Biochimie. 2014 Oct;105:4-11. doi: 10.1016/j.biochi.2014.06.016. Epub 2014 Jun 27. Biochimie. 2014. PMID: 24977933 Review.

10

Endoplasmic reticulum stress: an unrecognized actor in solid organ transplantation.

Pallet N, Fougeray S, Beaune P, Legendre C, Thervet E, Anglicheau D. Pallet N, et al. Among authors: beaune p. Transplantation. 2009 Sep 15;88(5):605-13. doi: 10.1097/TP.0b013e3181b22cec. Transplantation. 2009. PMID: 19741454 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results